» Articles » PMID: 34220545

Cardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression

Overview
Journal Front Physiol
Date 2021 Jul 5
PMID 34220545
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiac and renal function are inextricably connected through both hemodynamic and neurohormonal mechanisms, and the interaction between these organ systems plays an important role in adaptive and pathophysiologic remodeling of the heart, as well as in the response to renally acting therapies. Insufficient understanding of the integrative function or dysfunction of these physiological systems has led to many examples of unexpected or incompletely understood clinical trial results. Mathematical models of heart and kidney physiology have long been used to better understand the function of these organs, but an integrated model of renal function and cardiac function and cardiac remodeling has not yet been published. Here we describe an integrated cardiorenal model that couples existing cardiac and renal models, and expands them to simulate cardiac remodeling in response to pressure and volume overload, as well as hypertrophy regression in response to angiotensin receptor blockers and beta-blockers. The model is able to reproduce different patterns of hypertrophy in response to pressure and volume overload. We show that increases in myocyte diameter are adaptive in pressure overload not only because it normalizes wall shear stress, as others have shown before, but also because it limits excess volume accumulation and further elevation of cardiac stresses by maintaining cardiac output and renal sodium and water balance. The model also reproduces the clinically observed larger LV mass reduction with angiotensin receptor blockers than with beta blockers. We further provide a mechanistic explanation for this difference by showing that heart rate lowering with beta blockers limits the reduction in peak systolic wall stress (a key signal for myocyte hypertrophy) relative to ARBs.

Citing Articles

An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study.

Sang L, Zhou Z, Luo S, Zhang Y, Qian H, Zhou Y Pharm Res. 2023; 41(2):247-262.

PMID: 38148384 PMC: 10879352. DOI: 10.1007/s11095-023-03644-4.


Understanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling.

Basu S, Yu H, Murrow J, Hallow K PLoS Comput Biol. 2023; 19(11):e1011598.

PMID: 37956217 PMC: 10703410. DOI: 10.1371/journal.pcbi.1011598.


Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences.

Ndiaye J, Nekka F, Craig M Pharmaceutics. 2023; 15(3).

PMID: 36986862 PMC: 10052171. DOI: 10.3390/pharmaceutics15031002.


Mathematical modeling of antihypertensive therapy.

Kutumova E, Kiselev I, Sharipov R, Lifshits G, Kolpakov F Front Physiol. 2023; 13:1070115.

PMID: 36589434 PMC: 9795234. DOI: 10.3389/fphys.2022.1070115.


Thoroughly Calibrated Modular Agent-Based Model of the Human Cardiovascular and Renal Systems for Blood Pressure Regulation in Health and Disease.

Kutumova E, Kiselev I, Sharipov R, Lifshits G, Kolpakov F Front Physiol. 2021; 12:746300.

PMID: 34867451 PMC: 8632703. DOI: 10.3389/fphys.2021.746300.


References
1.
Cadrin-Tourigny J, Shohoudi A, Roy D, Talajic M, Tadros R, Mondesert B . Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. JACC Heart Fail. 2017; 5(2):99-106. DOI: 10.1016/j.jchf.2016.10.015. View

2.
Faris R, Flather M, Purcell H, Poole-Wilson P, Coats A . Diuretics for heart failure. Cochrane Database Syst Rev. 2006; (1):CD003838. DOI: 10.1002/14651858.CD003838.pub2. View

3.
Arts T, Prinzen F, Snoeckx L, Rijcken J, Reneman R . Adaptation of cardiac structure by mechanical feedback in the environment of the cell: a model study. Biophys J. 1994; 66(4):953-61. PMC: 1275802. DOI: 10.1016/S0006-3495(94)80876-8. View

4.
Doshi D, Burkhoff D . Cardiovascular Simulation of Heart Failure Pathophysiology and Therapeutics. J Card Fail. 2015; 22(4):303-11. DOI: 10.1016/j.cardfail.2015.12.012. View

5.
Gaasch W, Zile M . Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011; 58(17):1733-40. DOI: 10.1016/j.jacc.2011.07.022. View